JP6816149B2 - 成長ホルモン欠乏症の検出および治療 - Google Patents

成長ホルモン欠乏症の検出および治療 Download PDF

Info

Publication number
JP6816149B2
JP6816149B2 JP2018534488A JP2018534488A JP6816149B2 JP 6816149 B2 JP6816149 B2 JP 6816149B2 JP 2018534488 A JP2018534488 A JP 2018534488A JP 2018534488 A JP2018534488 A JP 2018534488A JP 6816149 B2 JP6816149 B2 JP 6816149B2
Authority
JP
Japan
Prior art keywords
day
children
growth
test
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529766A5 (enExample
JP2018529766A (ja
Inventor
ソーンナー、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ammonett Pharma LLC
Original Assignee
Ammonett Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ammonett Pharma LLC filed Critical Ammonett Pharma LLC
Publication of JP2018529766A publication Critical patent/JP2018529766A/ja
Publication of JP2018529766A5 publication Critical patent/JP2018529766A5/ja
Application granted granted Critical
Publication of JP6816149B2 publication Critical patent/JP6816149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2018534488A 2015-09-21 2016-09-21 成長ホルモン欠乏症の検出および治療 Active JP6816149B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US62/221,191 2015-09-21
US201662289221P 2016-01-30 2016-01-30
US62/289,221 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020213095A Division JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療

Publications (3)

Publication Number Publication Date
JP2018529766A JP2018529766A (ja) 2018-10-11
JP2018529766A5 JP2018529766A5 (enExample) 2019-08-15
JP6816149B2 true JP6816149B2 (ja) 2021-01-20

Family

ID=58276481

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018534488A Active JP6816149B2 (ja) 2015-09-21 2016-09-21 成長ホルモン欠乏症の検出および治療
JP2020213095A Active JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療
JP2022110116A Active JP7389862B2 (ja) 2015-09-21 2022-07-08 成長ホルモン欠乏症の検出および治療
JP2023195764A Active JP7724831B2 (ja) 2015-09-21 2023-11-17 成長ホルモン欠乏症の検出および治療
JP2025130430A Pending JP2025170274A (ja) 2015-09-21 2025-08-05 成長ホルモン欠乏症の検出および治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020213095A Active JP7104768B2 (ja) 2015-09-21 2020-12-23 成長ホルモン欠乏症の検出および治療
JP2022110116A Active JP7389862B2 (ja) 2015-09-21 2022-07-08 成長ホルモン欠乏症の検出および治療
JP2023195764A Active JP7724831B2 (ja) 2015-09-21 2023-11-17 成長ホルモン欠乏症の検出および治療
JP2025130430A Pending JP2025170274A (ja) 2015-09-21 2025-08-05 成長ホルモン欠乏症の検出および治療

Country Status (23)

Country Link
US (5) US9763919B2 (enExample)
EP (3) EP3352752B1 (enExample)
JP (5) JP6816149B2 (enExample)
KR (4) KR20230116961A (enExample)
CN (2) CN108348501A (enExample)
AU (5) AU2016328969B2 (enExample)
CA (1) CA2998523C (enExample)
CY (1) CY1125183T1 (enExample)
DK (2) DK3939590T3 (enExample)
ES (2) ES2967259T3 (enExample)
FI (1) FI3939590T3 (enExample)
HR (1) HRP20220317T1 (enExample)
HU (2) HUE065224T2 (enExample)
IL (1) IL258224B (enExample)
LT (1) LT3352752T (enExample)
PL (2) PL3939590T3 (enExample)
PT (2) PT3939590T (enExample)
RS (1) RS62988B1 (enExample)
SG (2) SG10202010598SA (enExample)
SI (1) SI3352752T1 (enExample)
SM (1) SMT202200167T1 (enExample)
UA (1) UA123865C2 (enExample)
WO (1) WO2017053373A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
EP3840854A4 (en) 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650597A4 (en) * 1992-06-29 1996-12-18 Univ South Florida DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH.
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU758160B2 (en) * 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Also Published As

Publication number Publication date
PT3352752T (pt) 2022-03-09
UA123865C2 (uk) 2021-06-16
US20170079961A1 (en) 2017-03-23
SG10202010598SA (en) 2020-11-27
AU2016328969B2 (en) 2020-10-08
ES2967259T3 (es) 2024-04-29
US12539293B2 (en) 2026-02-03
CN108348501A (zh) 2018-07-31
JP2024026112A (ja) 2024-02-28
PL3939590T3 (pl) 2024-03-25
EP3939590B1 (en) 2023-11-29
ES2908423T3 (es) 2022-04-29
PL3352752T3 (pl) 2022-04-19
HUE057831T2 (hu) 2022-06-28
HRP20220317T1 (hr) 2022-05-13
FI3939590T3 (fi) 2023-12-14
KR20250102122A (ko) 2025-07-04
AU2020233715B2 (en) 2021-09-30
CY1125183T1 (el) 2023-06-09
SG10201902424TA (en) 2019-04-29
JP7104768B2 (ja) 2022-07-21
HK1263178A1 (zh) 2020-01-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
AU2024201658A1 (en) 2024-04-04
JP7389862B2 (ja) 2023-11-30
US20220142989A1 (en) 2022-05-12
US10105352B2 (en) 2018-10-23
US10898472B2 (en) 2021-01-26
DK3939590T3 (da) 2023-12-18
AU2016328969A1 (en) 2018-04-26
KR20180082428A (ko) 2018-07-18
EP3352752A1 (en) 2018-08-01
IL258224A (en) 2018-05-31
JP2018529766A (ja) 2018-10-11
SMT202200167T1 (it) 2022-05-12
IL258224B (en) 2021-10-31
KR102385669B1 (ko) 2022-04-13
CA2998523C (en) 2023-08-01
NZ741142A (en) 2025-05-02
HUE065224T2 (hu) 2024-05-28
RS62988B1 (sr) 2022-03-31
JP2021063096A (ja) 2021-04-22
EP4296679A2 (en) 2023-12-27
US20190015394A1 (en) 2019-01-17
US20180071266A1 (en) 2018-03-15
CA2998523A1 (en) 2017-03-30
JP7724831B2 (ja) 2025-08-18
KR20220047407A (ko) 2022-04-15
AU2020233715A1 (en) 2020-10-22
AU2021254600A1 (en) 2021-11-18
US9763919B2 (en) 2017-09-19
KR20230116961A (ko) 2023-08-04
LT3352752T (lt) 2022-04-11
WO2017053373A1 (en) 2017-03-30
CN116459250A (zh) 2023-07-21
EP3939590A1 (en) 2022-01-19
AU2024201658B2 (en) 2025-10-30
JP2022163012A (ja) 2022-10-25
EP3352752B1 (en) 2021-12-22
AU2021254600B2 (en) 2024-02-15
KR102560838B1 (ko) 2023-07-27
SI3352752T1 (sl) 2022-05-31
JP2025170274A (ja) 2025-11-18
PT3939590T (pt) 2024-01-23
EP3352752A4 (en) 2019-06-12
US20250213536A1 (en) 2025-07-03
DK3352752T3 (da) 2022-02-28
EP4296679A3 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7104768B2 (ja) 成長ホルモン欠乏症の検出および治療
US11234969B2 (en) Detecting and treating growth hormone deficiency
HK40096494A (en) Detecting and treating growth hormone deficiency
HK40105706A (en) Detecting and treating growth hormone deficiency
HK40068057A (en) Detecting and treating growth hormone deficiency
HK40068057B (en) Detecting and treating growth hormone deficiency
HK1263178B (en) Detecting and treating growth hormone deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201223

R150 Certificate of patent or registration of utility model

Ref document number: 6816149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250